In conclusion, there is ongoing debate on the efficacy of medication for BD in individuals afflicted with comorbid substance use disorders and on the modifying effects of antipsychotic medication on the endogenous cannabinoid system (Hamdani et al., 2008; Wiley et al., 2008; Leweke and Koethe, 2008). BD cases with comorbid cannabis use disorders are a vulnerable population and continued efforts to identify integrated treatments for dually diagnosed patients is vital.
